220 related articles for article (PubMed ID: 32267475)
21. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
[TBL] [Abstract][Full Text] [Related]
22. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
23. Reticulated acanthoma with sebaceous differentiation: another sebaceous neoplasm associated with Muir-Torre syndrome?
Shon W; Wolz MM; Newman CC; Bridges AG
Australas J Dermatol; 2014 Nov; 55(4):e71-3. PubMed ID: 23651324
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
Shia J; Stadler Z; Weiser MR; Rentz M; Gonen M; Tang LH; Vakiani E; Katabi N; Xiong X; Markowitz AJ; Shike M; Guillem J; Klimstra DS
Am J Surg Pathol; 2011 Mar; 35(3):447-54. PubMed ID: 21297438
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
26. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
Neelakantan IV; Di Palma S; Smith CE; McCoombe A
Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Chapel DB; Yamada SD; Cowan M; Lastra RR
Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
[TBL] [Abstract][Full Text] [Related]
28. Sebaceous Neoplasms.
Flux K
Surg Pathol Clin; 2017 Jun; 10(2):367-382. PubMed ID: 28477886
[TBL] [Abstract][Full Text] [Related]
29. Deceptively Innocent Façade of Sebaceous Carcinoma in Muir-Torre Syndrome.
Cox SV; Smith J
Dermatol Surg; 2021 Jun; 47(6):828-829. PubMed ID: 33038102
[No Abstract] [Full Text] [Related]
30. Ocular Adnexal Adenomatoid Sebaceous Gland Hyperplasia: A Clinical and Immunopathologic Analysis in Relation to the Muir-Torre Syndrome.
Jakobiec FA; Cortes Barrantes P; Milman T; Lee NG; Fay A
Ophthalmic Plast Reconstr Surg; 2020; 36(1):e6-e12. PubMed ID: 31593035
[TBL] [Abstract][Full Text] [Related]
31. Multiple benign adnexal tumours: Anything but benign.
McCarthy RL; Thomas CL; Isaacs F
Australas J Dermatol; 2019 Aug; 60(3):234-236. PubMed ID: 30671930
[TBL] [Abstract][Full Text] [Related]
32. Sebaceous adenomas of the eyelid and Muir-Torre Syndrome.
Jagan L; Zoroquiain P; Bravo-Filho V; Logan P; Qutub M; Burnier MN
Br J Ophthalmol; 2015 Jul; 99(7):909-13. PubMed ID: 25595178
[TBL] [Abstract][Full Text] [Related]
33. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
Cohen PR; Kurzrock R
Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
[TBL] [Abstract][Full Text] [Related]
34. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.
Ponti G; Manfredini M; Pellacani G; Tomasi A
Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151
[TBL] [Abstract][Full Text] [Related]
35. MSH6 mutation in a family affected by Muir-Torre syndrome.
Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
[TBL] [Abstract][Full Text] [Related]
36. The role of immunohistochemistry in the Muir-Torre Syndrome.
Oliveira CM; Campos JG; Maia MR; Lobo LE; Valle FF
An Bras Dermatol; 2015; 90(3 Suppl 1):168-70. PubMed ID: 26312706
[TBL] [Abstract][Full Text] [Related]
37. Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome.
Plocharczyk EF; Frankel WL; Hampel H; Peters SB
Am J Dermatopathol; 2013 Apr; 35(2):191-5. PubMed ID: 22722469
[TBL] [Abstract][Full Text] [Related]
38. Reporting Subclonal Immunohistochemical Staining of Mismatch Repair Proteins in Endometrial Carcinoma in the Times of Ever-Changing Guidelines.
Scheiderer A; Riedinger C; Kimball K; Kilgore L; Orucevic A
Arch Pathol Lab Med; 2022 Sep; 146(9):1114-1121. PubMed ID: 34979565
[TBL] [Abstract][Full Text] [Related]
39. Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome.
Lamba AR; Moore AY; Moore T; Rhees J; Arnold MA; Boland CR
Fam Cancer; 2015 Jun; 14(2):259-64. PubMed ID: 25637498
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]